300138 晨光生物
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,732,327-4.71%6,871,5156,295,8734,873,6103,912,935
减:营业总成本1,687,057-0.04%6,450,8135,838,5774,525,7233,620,054
    其中:营业成本1,590,1350.26%6,073,5995,418,1474,154,5273,260,922
               财务费用21,568-21.70%47,35422,74250,78971,428
               资产减值损失(2,430)-418.88%4,056(31,224)(25,950)(19,326)
公允价值变动收益(38,867)-831.66%5,363(5,024)564--
投资收益32,774209.28%68,65138,47630,36911,930
    其中:对联营企业和合营企业的投资收益10,806364.67%13,12020,33617,95410,236
营业利润44,345-71.28%548,325487,010384,869311,055
利润总额44,254-71.55%555,819501,756398,066312,625
减:所得税费用11,260-27.87%61,64565,67147,46746,486
净利润32,993-76.42%494,173436,085350,599266,138
减:非控股权益(5,599)-214.27%14,4512,052(916)(1,603)
股东净利润38,592-71.42%479,722434,033351,514267,741

市场价值指针
每股收益 (元) *0.073-71.40%0.9020.8150.6650.554
每股派息 (元) *----0.1300.1600.1300.100
每股净资产 (元) *6.3101.56%6.5145.9405.2283.805
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容